REGENXBIO Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
REGENXBIO Inc. (RGNX) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $38.94 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $38.94M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $59.87M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $36.97M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $45.72M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-06-30 | $38.94M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $59.87M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $36.97M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $45.72M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $122.96M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $47.44M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $21.32M 10-K · filed 2026-03-05 |
| 2024-09-30 | $5.48M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $153.78M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $90.98M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $38.89M 10-K · filed 2025-03-13 |
| 2023-09-30 | $64.89M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $56.74M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $45.38M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $202.69M 10-K · filed 2024-02-27 |
| 2022-09-30 | $358.19M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $460.07M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $495.39M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $447.20M 10-K · filed 2023-02-28 |
| 2021-09-30 | $256.77M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $263.01M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $282.89M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $55.51M 10-K · filed 2022-03-01 |
| 2020-09-30 | $13.73M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $42.91M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $90.35M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $61.12M 10-K · filed 2020-02-26 |
| 2019-09-30 | $27.85M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $19.18M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $124.03M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $298.41M 10-K · filed 2019-02-27 |
| 2018-09-30 | $290.42M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $162.77M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |